Thermo Fisher acquires Novasep's viral vector manufacturing business


Adding Henogen S.A. furthers its efforts in cell and gene-based therapy development

Thermo Fisher Scientific Inc. and Groupe Novasep SAS, a services and technologies supplier for the life sciences industry, announced that Thermo Fisher has acquired Henogen S.A., Novasep’s viral vector manufacturing business in Belgium, for approximately €725 million (about $876 million) in cash.

Henogen S.A. will be part of Thermo Fisher's pharma services business within the laboratory products and services segment.

Between its two locations in Seneffe and Gosselies, Belgium, the business offers contract manufacturing services for both vaccines and therapies to biotech companies and large biopharma customers via approximately 75,347 square feet of capacity. The business' estimated 2020 revenue was €80 million (approximately $97 million).

Thermo Fisher previously announced plans to construct a 67,000-sq.-ft. plasmid DNA manufacturing facility in Carlsbad, CA last month.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.